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Abstract
Copy number variations (CNVs) have been previously associated with several different neurodevelopmental psychiatric
disorders, such as autism, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The present study consisted of
a pilot genome-wide screen for CNVs in a cohort of 16 patients with early-onset obsessive-compulsive disorder (OCD) and
12 mentally healthy individuals, using array-based comparative genomic hybridization (aCGH) on 44K arrays. A small rare
paternal inherited microdeletion (,64 kb) was identified in chromosome 15q13.3 of one male patient with very early onset
OCD. The father did not have OCD. The deletion encompassed part of the FMN1 gene, which is involved with the
glutamatergic system. This finding supports the hypothesis of a complex network of several genes expressed in the brain
contributing for the genetic risk of OCD, and also supports the glutamatergic involvement in OCD, which has been
previously reported in the literature.
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Introduction
Twin and family studies provide strong evidence of the
importance of genetic factors for the expression of obsessive-
compulsive disorder (OCD) and other disorders in the obsessive-
compulsive spectrum [1]. To date, more than 100 positional and
functional candidate genes related to serotonin, dopamine, and
glutamate transmission have been implicated in these disorders
[2]. However, most of the findings have not been replicated. A
recent meta-analysis of all genetic association studies of OCD,
which provided sufficient information for data extraction, found
that the disorder was associated with serotonin-related polymor-
phisms (5-HTTLPR and HTR2A) and that there may be
significant sex differences in the genetic bases of the disease, with
only male OCD patients carrying polymorphisms involved in
catecholamine modulation (COMT and MAOA) [3]. Secondary
analyses of polymorphisms examined in fewer than five data sets
identified other candidate polymorphisms associated with trophic
factors, neurotransmitters, and with an immunologic factor [3].
The first Genome-Wide Association Study (GWAS) of OCD,
which was recently published, analyzed 400 trios, 1,465 cases and
5,557 controls having found no associations between any SNPs
(single nucleotide polymorphisms) and OCD at a genome-wide
significant level in the combined trio-case-control sample. It is
worth mentioning, however, that the top-ranked SNPs were
related to transcriptional regulation and to glutamatergic neuro-
transmission and signaling [4].
Recently, the original genetic model for psychiatric disorders,
which explained these conditions as resulting from the effect of
common genetic variants (.1% frequency), has been challenged
by a model involving high impact variants which are individually
rare, but collectively common [5]. Research has shown that,
although SNPs outnumber CNVs (copy number variations) in the
genome by three orders of magnitude, their relative contribution
to genome variation is similar [6]. Therefore, as could be expected
from these observations, the study of CNV has allowed a more
comprehensive understanding of disease etiology, bringing rare
variants to the forefront [7].
Early studies analyzed CNVs ranging from one kilobase (kb) to
several megabases (Mb) in size, including large insertions or
deletions in the genome. However, the increased accuracy of
detection techniques has allowed the identification of smaller
CNVs, so that many recent studies involve the analysis of
fragments smaller than 1 kb [8].
CNVs are especially relevant to the study of mental disorders, as
they have been causally associated with neurodevelopmental
disorders and learning disabilities [9]. Specific rare CNVs have
also been found to be associated with autism, schizophrenia, and
attention-attention deficit hyperactivity disorder (ADHD) [10–14].
The current hypothesis for the etiology of mental disorders
suggests that these conditions are polygenic, and that both
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common and rare variations contribute to their development.
Therefore, rather than consisting of risk factors for specific
conditions, CNVs are thought to confer broad susceptibility to a
variety of neurodevelopmental disorders. Large, rare CNVs are
more pathogenic, and are more likely to be under negative
evolutionary selection [15]. Although CNVs with smaller effect
sizes may also have an important role in the etiology of mental
disorders, their individual influences and the impact of their
interaction with other CNVs on the development of mental
illnesses have been poorly studied [16].
To date, few studies have investigated CNVs in OCD patients.
One study was conducted to search for CNVs in these individuals
screened for 15q11-13 and 22q11.2 microrearrangements associ-
ated with Prader-Willi and DiGeorge Syndromes (DGS). The
study was performed in 236 OCD probands using Multiplex
Ligation-dependent Probe Amplification (MLPA), which allows
the relative quantification of the copy number in at least 50
sequences in a single experiment. The study did not detect any
CNVs in these regions, possibly due to the rare prevalence of these
chromosomal anomalies in OCD and due to the exclusion of
significant mental retardation in the samples studied [17]. Studies
have shown that pathogenic CNVs are more prevalent among the
individuals with moderate and severe intellectual disability, which
are usually exclusionary criteria of research protocols [18].
Another study by Hooper et al., (2012) used cytogenetic analysis
and fluorescence in situ hybridization (FISH) to identify an
apparently balanced cytogenetic chromosome translocation
t(6;22)(q16.2;p13) that segregated from the mother with OCD to
her male son with Tourette Syndrome (TS) and OCD. Whole
genome mate-pair sequencing and high resolution SNP array
analysis was performed in the male proband to identify any related
or additional sub-microscopic rearrangements. The largest
heterozygous deletion identified in this secondary analysis was a
400 kb deletion located 1.3 Mb telomeric to the chromosome 6q
breakpoint. This deletion caused heterozygous loss of all coding
sequences of the GPR63, NDUFA4 and KLHL32 genes which
are expressed in the brain [19]. In addition, this deletion coincides
with a rearrangement previously reported in a girl diagnosed with
Autism Spectrum Disorder (ASD) and developmental delay [20].
In a study of 136 cases of children and adolescents with OCD
compared with 106 healthy age-matched controls, Walitza et al.,
(2011) reported that the deletion (one copy) of a small (100 bp)
CNV localized near (68-bp upstream the rs 6311 in the promoter
region of the HTR2A gene was associated to a very early-onset
and to symptom severity of OCD. The frequency of this deletion
was increased in the OCD group (n = 8) when compared to
healthy controls (n = 1), and carriers of one copy (deletion) of the
CNV were associated with a very-early-onset OCD and increased
CY-BOCS scores [21].
The first genome-wide CNV analysis in OCD (1,613 patients)
and the largest to date in Tourette Syndrome (TS) (1,086 patients)
and 720 ancestry-matched controls was conducted to observe the
effects of specific neurodevelopmental CNVs. The analyses were
restricted to large (.500 kb an rare (,1% frequency in the
Database of Genomic Variants-DGV) CNVs, using Illumina
genotyping array. The results showed evidence for an increased
burden of pathogenic neurodevelopmental deletions in OCD/TS
patients compared with controls. Deletion at 16p13.11 was
primarily associated with OCD, however 3 de novo CNVs in
this region among 6 cases with OCD/TS point to the possibility of
pleiotropic effect of this locus. These deletions at 16p13.11 have
been extended to other neurodevelopmental disorders, including
developmental delay, seizures, and autism [22].
In light of these findings and given our long-standing interest in
the contribution of genetic variation to OCD, we conducted a
preliminary study to identify rare CNVs in 16 patients with early-
onset OCD and 12 controls, using array-based comparative
genomic hybridization (aCGH).
Materials and Methods
The present study was approved by the Research Ethics
Committees of the University of Sa˜o Paulo School of Medicine, as
well as by the Brazilian National Commission of Research Ethics
(CONEP, process number: 16756). All participating subjects gave
written informed consent.
The study was conducted in the Outpatient Clinic of the
Obsessive-Compulsive Spectrum Disorders Program of the
Institute of Psychiatry at the General Hospital of the University
of Sa˜o Paulo, School of Medicine.
Patients were referred from primary psychiatric services, or
recruited through television, radio, and newspaper announce-
ments. Healthy controls were recruited from university staff and
students, hospital staff or by word of mouth.
Patients and healthy controls were assessed at baseline with the
Structured Clinical Interview for DSM-IV Axis I Disorders and
additional modules for tic and impulse control disorders, the
ADHD and separation anxiety sections of the Kiddie Schedule for
Affective Disorders and Schizophrenia (K-SADS), the Yale-Brown
Obsessive- Compulsive Scale (Y-BOCS), the Dimensional Yale-
Brown Obsessive- Compulsive Scale (DY-BOCS), the Yale Global
Tic Severity Scale (YGTSS), and the Beck Depression (BDI) and
Anxiety (BAI) Inventories [23,24]. Patients were included if they
were aged between 18 and 65 years and had OCD as the primary
diagnosis according to DSM-IV criteria. Healthy controls were
included if they were aged between 18 and 65 years and did not
have OCD, tic or impulse control disorders, ADHD, anxiety
disorders or major depression according to the DSM-IV.
Subjects with a primary diagnosis of a psychotic disorder or with
any other condition that could impair their understanding of the
protocol questions were excluded. Patients with a clinical
condition that could hamper the interpretation of the results,
such as those whose OCD symptoms began after significant head
trauma or were secondary to other neurological disorders and
intellectual disability were also excluded.
Genomic DNA extraction
In those patients from whom it was possible to obtain blood
samples, peripheral blood leukocytes were used as a source of
DNA, which was extracted using the salting out method [25]. For
the eight subjects from whom blood samples could not be drawn,
DNA was extracted from saliva samples collected using the
Oragene kit manufactured by Genotek according to the protocols
available at http://www.dnagenotek.com/.
Comparative genomic hybridization based on microarray
(aCGH)
Array-CGH analysis was performed using an oligonucleotide
44 K whole-genome microarray platform (design 14950, Agilent
Technologies, Santa Clara, USA). The platform was composed of
44,290 60-mer oligonucleotide probes for mapped genes or unique
DNA sequences with an average spatial resolution of ,30–35 kb.
However, the platform does not cover the pseudoautosomal
regions of the X and the Y chromosomes. The genomic DNA of
patients and healthy controls was labeled with Cy3-fluorophores,
while the reference DNA was labeled with Cy5-fluorophore.
These were hybridized to the array in the presence of Cot-1 DNA,
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a blocking reagent which suppresses the nonspecific hybridization
of repetitive sequences.
Test DNA samples were hybridized with gender matched
reference DNA, which consisted of a pooled sample of human
placenta DNA obtained from ten normal individuals. Purification,
hybridization, and washing were carried out according to the
manufacturer’s instructions. Slides were read by a GenePix 4000B
scanner, and the scanned images of the arrays were processed
using the Feature Extraction software package (Agilent Technol-
ogies, Santa Clara, CA, USA). Fluorescence intensity was
measured by the Feature Extraction software, version 9.5, using
an Agilent whole human genome 4644k microarray. Further
details on the protocols used are available online (http://www.
home.agilent.com/).
These analyses were performed in all patients, healthy controls
and additionally, in the parents of one patient who had one rare
CNV.
Selection of high-confidence copy number alterations
Constitutive or germline CNVs were identified using the
Genomic Workbench software (Agilent Technologies, Santa
Clara, CA, USA) with the statistical algorithm ADM-2, and a
6.7 sensitivity threshold. Poor quality hybridizations (QC.0.3)
were discarded. For samples that passed quality control, CNV
calling (deletions and duplications) was performed using the Nexus
Copy Number 5.0 software, with a quality control threshold of ,
0.18. CNVs were called in Nexus using the FASST2 segmentation
algorithm; with at least three affected probes and default settings
(threshold log2 ratio of 0.3 or 1.14 for gain or high copy gain, and
20.3 and 21.14 for loss and homozygous loss, respectively), and
significance threshold set to 1.0E-6.
Samples that did not meet quality thresholds were excluded
from further analysis, as were microarrays with low quality
according to visual inspection. Although the initial sample was
composed of 20 patients and 20 controls, 12 samples were
subsequently excluded for quality reasons (4 patients and 8
controls).
CNVs were considered rare if they showed less than 50%
overlap with CNVs predicted with frequency of at least 1%
according to the March 2010 update of the Database of Genomic
Variants (DGV). The confirmation of rare CNVs and determina-
tion of the parent of origin were conducted using 60 K SNP array
analysis. Furthermore, rare CNVs were confirmed by quantitative
PCR (qPCR).
Quantitative PCR (qPCR) validation
Rare CNVs were validated using the SYBR Green system from
Applied Biosystems 7500 Real-Time PCR System. Two qPCR
primers were designed and mapped against the NCBI reference
sequence hg18 to obtain converging evidence for the detected
CNVs. Primer sequences were as follows: FMN1 forward primer:
59 CAGGTTTGTCTGAAAGTCACC 39, reverse primer: 59
CTACTCTTTGTACCTGGGAGGAC -39. The absolute num-
ber of gene copies was normalized using the GAPDH and P2RX7
genes (control genes). Triplicates were analyzed using the
comparative 22DDCt-cycle threshold method [26]. Values in the
0.8–1.2 range indicated duplication, ,0.6 were indicative of
deletions, and values.1.4 were considered duplications (Figure 1).
Statistical Analysis
We assessed the impact of CNVs in cases compared to controls
using five measures: the number of CNVs per individual, the
estimated CNV size, the percentage of CNVs that overlapped with
CNVs in the DGV (overlap with.50% of length), and the
percentage of CNVs in two different groups of CNV sizes
(CNVs.1 Mb and CNVs.100 kb – 999 kb). P-values were
calculated using two-tailed Fisher exact test and were shown for
each comparison between cases and controls. The level of
significance considered was alpha = 0.05 (Table 1).
We compared the proportion of subjects in each group
harboring CNVs with sizes between 30 kb–500 kb and.500 kb.
This last comparison was conducted to observe whether CNVs
involved with neurodevelopment disorder were associated with the
OCD group [6]. Pearson’s Chi-square (two-tailed) p-values were
calculated, using a pre-determined p-value threshold that correct-
ed for 2 primary comparisons using a standard Bonferroni
approach (p,0.025) [Table 2].
Results
After completing quality control and case-control matching, 12
samples were excluded (4 cases and 8 controls). Therefore, a total
of 16 cases and 12 controls were included in the final analyses. The
mean age at symptom onset in the patient group was 9.8 years
(SD = 4.03) and the mean Y-BOCS score was 30.4 (SD = 4.93).
Characteristics of CNVs in patients and controls
The median CNV size in OCD patients was 435.4 kb and the
median number of CNVs per individual was 3, with 11.3% of
these events consisting of deletions (the remaining were all
duplications). A total of 24.5% of CNVs in OCD patients
were.1 Mb, while 67.9% of variants were in the 100-999 kb
range. Patients and controls did not significantly differ with respect
to these characteristics (Table 1).
Overall, no statistically significant differences in CNV size were
found between cases and controls, even when a nominal
uncorrected p-value of 0.05 was used. Similar results were
obtained with regard to between-group differences in the
frequency of CNV occurrence (Table 1 and Table 2).
Rare CNVs analyses
One OCD patient was found to carry a rare CNV consisting of
an intragenic,64 kb microdeletion at 15q13.3 encompassing part
of the FMN1 gene. Array CGH analyses of the patient’s parents
were performed to verify whether the CNV was de novo or
inherited. The microdeletion was found to be inherited from a
non-affected father (Figure 1).
Discussion
In this study an early-onset OCD patient (age of first obsessive-
compulsive symptoms when he was 8 years old) was found to carry
a rare intragenic ,64 kb microdeletion at 15q13.3. This
microdeletion was present in the father who did not have OCD.
The mother also did not have OCD, although his sister also had
OCD. Unfortunately the sister did not agree to participate in the
study.
This CNV encompasses two exons of the FMN1 gene, which
encodes the protein Formin1. The overexpression of Formin1b
produces an increase in the number of primary dendrites in
cultured hippocampal neurons and an increase in the number of
glutamatergic synaptic inputs [27]. Additionally, it is thought that
Formin1 may mediate the effect of the proneural transcription
factor Ngn3, which regulates dendritogenesis and synaptogenesis
[28].
The genetic findings in OCD has shown dysregulation in genes
that are expressed in the brain and are involved in the
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glutamatergic, serotonergic and dopaminergic pathways playing
an important part in the expression of OCD [2].
Recent evidence from a number of studies has highlighted the
role of glutamatergic synaptic dysfunctions in the cortico-striatal-
thalamo-cortical (CSTC) circuit in the etiology of OCD and
related disorders [29]. According to a number of independent
reports, one of the strongest candidate genes for OCD is the
neuronal glutamate transporter gene SLC1A1 (Solute Carrier,
Family 1, Member 1) [30–32]. In fact, this is the only gene whose
association with OCD has been replicated in independent samples
[4]. However, it is interesting to note that the previously
mentioned GWAS of OCD did not find any polymorphisms in
the SLC1A1 gene, although it did associate the disorder with a
number of genes involved in glutamatergic processes. These
findings corroborate the hypothesis that genes involved in the
glutamatergic system may contribute to the pathophysiology of
OCD [33,34].
The OCD Collaborative Genetics Study (OCGS) conducted a
linkage analysis on 376 affected families using genetic association
methods, and found that the SNPs most strongly associated with
OCD were in chromosome 15q. Several of those SNPs are located
in or near the FMN1 gene. One SNP (rs2306277) in particular,
located in exon 1 of the FMN1 gene, was predicted by PolyPhen 2
(a tool which predicts the possible impact of an amino acid
Figure 1. Chromosome 15q 13.3 after CNV and qPCR procedures. A. The microdeletion identified in the FMN1 region of chromosome
15q13.3 using Genomic Workbench software (Agilent Technologies, Santa Clara, CA, USA). B. Genome browser image of the region containing the
FMN1 gene. One rare deletion was identified in the male proband (64 kb loss in OCD case 222_3). C. Rare CNVs were validated by SYBR Green-based
real time PCR, and it was found that the father and son had only one copy of the exon while the gender-matched control had two copies.
doi:10.1371/journal.pone.0110198.g001
Table 1. Characteristics of all copy number variations (CNVs) in obsessive-compulsive disorder (OCD) patients and controls.
OCD patients (n =16) Controls (n=12) P-value
All CNVs All CNVs
Samples with CNVs 16 12 0.4497
Number of CNVs 53 48 0.6188
Median number of CNVs per genome 3 2 0.6547
Median CNV size (kb) 435.4 389.8 0.1124
% Gain/Loss 88.6/11.3 85.4/14.5 0.8083/0.5287
Overlapping CNVs (%)1 58.4 68.7 0.3609
CNVs.1 Mb (%) 24.5 20.8 0.5825
CNVs.100 kb – 999 kb (%) 67.9 79.1 0.3556
P-values were calculated using two-tailed Fisher exact test.
1Overlapping CNVs = percentage of CNVs that overlap with CNVs in the DGV (overlap with.50% of length).
doi:10.1371/journal.pone.0110198.t001
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substitution on the structure and function of a human protein) to
be a missense mutation with probable protein damage. The same
study also found SNPs associated with OCD in the same
chromosomal region (15q), but in the homeobox genes MEIS2
and NANOGP8, which code for transcription factors or closely
related proteins, all of which play an important role in
neurodevelopment [35]. Other studies have also reported associ-
ations between OCD and the 15q region, although none has
identified relevant SNPs in the region of the FMN1 gene itself
[36,37].
The main CNVs associated with psychiatric disorders have
generally been rare variants in genes involved in synaptogenesis,
neuronal and axonal mobility, protein degradation via the
ubiquitin-proteasome system (ubiquitin signaling), protein com-
plexes and postsynaptic signaling [11,12,38–48]. Studies have also
suggested that the CNVs found in psychiatric probands are often
in chromosomal regions associated with microdeletion syndromes,
such as loci 16p11.2 and 7q11.23, both associated with Williams
Syndrome, locus 15q11-13, associated with Prader-Willi and
Angelman Syndromes, and, lastly, locus 22q11.2, which has been
associated with DiGeorge syndrome [6].One of the most
interesting observations in psychiatric genetic association studies
has been the wide variability in the neuropsychiatric phenotype
associated with one individual CNV or CNV region [49,50].
These findings are consistent with the hypothesis linking the
known pleiotropic effects of these CNVs with shared abnormalities
in early neural development [51].
Interestingly, a microduplication at 15q13.3 (including the first
four exons of the CHRNA7 gene) was found in a proband with
TS, ADHD and OCD and his mother who had subclinical
ADHD. The other brother with TS and OCD (without ADHD)
did not have this duplication. The authors suggest that this
duplication may have an intermediate penetrance effect and may
be involved with ADHD development [52].
Studies have described a broad variety of phenotypes associated
with 15q13.3 deletion, including schizophrenia, epilepsy, autism,
antisocial behaviors and mental retardation [36,37,53–56]. The
frequency of these deletions in control individuals has been found
to be much lower than in cases. Additionally, the types of deletions
and duplications may vary between these individuals. The authors
suggest that submicroscopic deletions and duplications in this
region are associated with milder phenotypes, have less than 100%
penetrance, and tend to be inherited in a larger fraction of cases.
Environmental factors may also be important in explaining the
lack of penetrance [57]. However, none of the studies cited herein
have reported the microdeletion found in the present study. This
may suggest a pleiotropic effect whereby multiple variants in the
same region are associated with different phenotypes [58]. Perhaps
the microdeletion found in the present study in conjunction with
environmental factors or other genetic variants may contribute for
the manifestation of OCD. The overall rate of de novo large CNVs
(.500 kb) in OCD trio samples was 1.44%, which is intermediate
between healthy controls and autism (1.8% multiplex and 3.9%
simplex) and schizophrenia (2%–3%). This finding gives some
support to the involvement of CNVs in OCD, despite this study
was unable to call CNVs smaller than 500 kb due to technical
limitations. There is still the possibility that smaller CNVs may be
related to OCD [22].
Several limitations of the present study are worth mentioning.
Firstly, the sample size was small, particularly for the purposes of
the detection and analysis of rare CNVs. Although this association
may have happened by chance alone, other possibilities such as
incomplete penetration can be taken into account. Examining the
affected sister could help understand this issue.
Furthermore, even though the 44 K platform allows for the
observation of large and rare CNVs; the probe spacing may affect
the accuracy of CNV length measurements. Future analyses
should be conducted using larger sample sizes and a better
platform resolution. However, regardless of these limitations, the
present findings give further support to the hypothesis that many
variations in genes that function in a brain network can be related
with OCD, instead of single genes that simply cumulatively add
risk.
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